On 7 March 2022, Shenzhen Stock Exchange announced that Keymed Biosciences Inc. (2162.HK) was officially incorporated in the list of Shanghai and Shenzhen Stock Connect. Qualified domestic investors may directly trade in the company’s shares through Shanghai and Shenzhen Stock Connect.
The company is also included in eight Hang Seng indexes including the Hang Seng Composite Index (HSCI), Hang Seng Healthcare Index and Hang Seng Stock Connect Hong Kong Index.
Keymed was listed on the Main Board of the Hong Kong Stock Exchange in July 2021 and was included in the Hang Seng Hong Kong-Listed Biotech Index in November of the same year. The incorporation of the company in the said Stock Connect and the eight indexes including the HSCI proved again the company's strong R&D capability and stable business growth. With continuous focus on innovation and R&D, Keymed is committed to providing patients with more high-quality, affordable and innovative therapies to address the urgent clinical demands.